The Arginine Paradox - do L-arginine based NO boosters really work?
Why doesn't arginine supplementation and arginine based “nitric oxide boosters” work as advertised?
The Arginine Paradox
How L-arginine supplementation works in the context of elevated ADMA levels
How to combat elevated ADMA levels?
Will L-arginine supplementation benefit you?
1. Bloomer, R.J., Nitric oxide supplements for sports. Strength and Conditioning Journal, 2010. 32(2): p. 14-20.
2. Bloomer, R.J., et al., Comparison of pre-workout nitric oxide stimulating dietary supplements on skeletal muscle oxygen saturation, blood nitrate/nitrite, lipid peroxidation, and upper body exercise performance in resistance trained men. J Int Soc Sports Nutr, 2010. 7: p. 16.
3. Bode-Boger, S.M., et al., L-arginine infusion decreases peripheral arterial resistance and inhibits platelet aggregation in healthy subjects. Clin Sci (Lond), 1994. 87(3): p. 303-10.
4. Giugliano, D., et al., The vascular effects of L-Arginine in humans. The role of endogenous insulin. J Clin Invest, 1997. 99(3): p. 433-8.
5. Alvares, T.S., et al., L-Arginine as a potential ergogenic aid in healthy subjects. Sports Med, 2011. 41(3): p. 233-48.
6. Wax, B., et al., Acute L-arginine alpha ketoglutarate supplementation fails to improve muscular performance in resistance trained and untrained men. J Int Soc Sports Nutr, 2012. 9(1): p. 17.
7. Bode-Boger, S.M., et al., L-arginine-induced vasodilation in healthy humans: pharmacokinetic-pharmacodynamic relationship. Br J Clin Pharmacol, 1998. 46(5): p. 489-97.
8. Schwedhelm, E., et al., Pharmacokinetic and pharmacodynamic properties of oral L-citrulline and L-arginine: impact on nitric oxide metabolism. Br J Clin Pharmacol, 2008. 65(1): p. 51-9.
9. Robinson, T.M., D.A. Sewell, and P.L. Greenhaff, L-arginine ingestion after rest and exercise: effects on glucose disposal. Med Sci Sports Exerc, 2003. 35(8): p. 1309-15.
10. Vallance, P. and N. Chan, Endothelial function and nitric oxide: clinical relevance. Heart, 2001. 85(3): p. 342-50.
11. Boger, R.H. and S.M. Bode-Boger, The clinical pharmacology of L-arginine. Annu Rev Pharmacol Toxicol, 2001. 41: p. 79-99.
12. Gokce, N., L-arginine and hypertension. J Nutr, 2004. 134(10 Suppl): p. 2807S-2811S; discussion 2818S-2819S.
13. Higashi, Y., et al., Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans. Hypertension, 1997. 30(2 Pt 1): p. 252-8.
14. Clarkson, P., et al., Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest, 1996. 97(8): p. 1989-94.
15. Kawano, H., et al., Endothelial dysfunction in hypercholesterolemia is improved by L-arginine administration: possible role of oxidative stress. Atherosclerosis, 2002. 161(2): p. 375-80.
16. Adams, M.R., et al., Oral L-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis, 1997. 129(2): p. 261-9.
17. Sydow, K., C.E. Mondon, and J.P. Cooke, Insulin resistance: potential role of the endogenous nitric oxide synthase inhibitor ADMA. Vasc Med, 2005. 10 Suppl 1: p. S35-43.
18. Piatti, P.M., et al., Long-term oral L-arginine administration improves peripheral and hepatic insulin sensitivity in type 2 diabetic patients. Diabetes Care, 2001. 24(5): p. 875-80.
19. Pieper, G.M., W. Siebeneich, and L.A. Dondlinger, Short-term oral administration of L-arginine reverses defective endothelium-dependent relaxation and cGMP generation in diabetes. Eur J Pharmacol, 1996. 317(2-3): p. 317-20.
20. Bode-Boger, S.M., et al., Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med, 2003. 8(2): p. 77-81.
21. Heffernan, K.S., et al., L-arginine as a nutritional prophylaxis against vascular endothelial dysfunction with aging. J Cardiovasc Pharmacol Ther, 2010. 15(1): p. 17-23.
22. Boger, R.H., J.P. Cooke, and P. Vallance, ADMA: an emerging cardiovascular risk factor. Vasc Med, 2005. 10 Suppl 1: p. S1-2.
23. Cooke, J.P., ADMA: its role in vascular disease. Vasc Med, 2005. 10 Suppl 1: p. S11-7.
24. Boger, R.H., Asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, explains the "L-arginine paradox" and acts as a novel cardiovascular risk factor. J Nutr, 2004. 134(10 Suppl): p. 2842S-2847S; discussion 2853S.
25. Sibal, L., et al., The Role of Asymmetric Dimethylarginine (ADMA) in Endothelial Dysfunction and Cardiovascular Disease. Curr Cardiol Rev, 2010. 6(2): p. 82-90.
26. Cooke, J.P., Asymmetrical dimethylarginine: the Uber marker? Circulation, 2004. 109(15): p. 1813-8.
27. Tran, C.T., J.M. Leiper, and P. Vallance, The DDAH/ADMA/NOS pathway. Atheroscler Suppl, 2003. 4(4): p. 33-40.
28. Tsikas, D., et al., Assessment of nitric oxide synthase activity in vitro and in vivo by gas chromatography-mass spectrometry. J Chromatogr B Biomed Sci Appl, 2000. 742(1): p. 143-53.
29. Boger, R.H., P. Vallance, and J.P. Cooke, Asymmetric dimethylarginine (ADMA): a key regulator of nitric oxide synthase. Atheroscler Suppl, 2003. 4(4): p. 1-3.
30. Bode-Boger, S.M., F. Scalera, and L.J. Ignarro, The L-arginine paradox: Importance of the L-arginine/asymmetrical dimethylarginine ratio. Pharmacol Ther, 2007. 114(3): p. 295-306.
31. Boger, R.H., et al., Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease. J Am Coll Cardiol, 1998. 32(5): p. 1336-44.
32. Sydow, K., et al., ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of L-arginine and B vitamins. Cardiovasc Res, 2003. 57(1): p. 244-52.
33. Boger, R.H., et al., Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation, 1998. 98(18): p. 1842-7.
34. Boger, R.H. and C. Zoccali, ADMA: a novel risk factor that explains excess cardiovascular event rate in patients with end-stage renal disease. Atheroscler Suppl, 2003. 4(4): p. 23-8.
35. Cooke, J.P. and Y.T. Ghebremariam, DDAH says NO to ADMA. Arterioscler Thromb Vasc Biol, 2011. 31(7): p. 1462-4.
36. Cooke, J.P., DDAH: a target for vascular therapy? Vasc Med, 2010. 15(3): p. 235-8.
37. Asagami, T., et al., Metformin treatment lowers asymmetric dimethylarginine concentrations in patients with type 2 diabetes. Metabolism, 2002. 51(7): p. 843-6.
38. Stuhlinger, M.C., et al., Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA, 2002. 287(11): p. 1420-6.
39. Ito, A., et al., Renin-angiotensin system is involved in the mechanism of increased serum asymmetric dimethylarginine in essential hypertension. Jpn Circ J, 2001. 65(9): p. 775-8.
40. Delles, C., et al., Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens, 2002. 15(7 Pt 1): p. 590-3.